Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/22174Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Krallis, N. | en |
| dc.contributor.author | Cholevas, V. | en |
| dc.contributor.author | Mavridis, A. | en |
| dc.contributor.author | Georgiou, I. | en |
| dc.contributor.author | Bourantas, K. | en |
| dc.contributor.author | Andronikou, S. | en |
| dc.date.accessioned | 2015-11-24T19:22:35Z | - |
| dc.date.available | 2015-11-24T19:22:35Z | - |
| dc.identifier.issn | 0902-4441 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/22174 | - |
| dc.rights | Default Licence | - |
| dc.subject | 2,3-Diphosphoglycerate/blood | en |
| dc.subject | Adenosine Triphosphate/blood | en |
| dc.subject | Anemia/drug therapy/*prevention & control | en |
| dc.subject | Energy Metabolism | en |
| dc.subject | Erythrocytes/*metabolism | en |
| dc.subject | Erythropoietin/blood/*therapeutic use | en |
| dc.subject | Follow-Up Studies | en |
| dc.subject | Gestational Age | en |
| dc.subject | Humans | en |
| dc.subject | Infant, Newborn | en |
| dc.subject | *Infant, Premature | en |
| dc.subject | Phosphates/*blood | en |
| dc.subject | Prospective Studies | en |
| dc.subject | Receptors, Transferrin/blood | en |
| dc.subject | Recombinant Proteins | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Effect of recombinant human erythropoietin in preterm infants | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/10480285 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1999 | - |
| heal.abstract | Twenty-five premature infants (mean gestational age+/-SD, 31.4+/-1.9 weeks) were administered subcutaneously recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week beginning on the third day of life and continuing for 6 weeks. The controls (n=23) were premature infants with a mean gestational age of 32.2+/-2.3 weeks who did not receive rHuEpo. Haematological indices, haemoglobin and serum phosphate (Pi), and red blood cell (RBC) phosphate metabolites (ATP, 2,3-DPG, RBCPi) were tested monthly until the 6th month and thereafter at the 9th and 12th months of life. The level of serum soluble transferrin receptors (sTfR) correlated significantly with rHuEpo (p<0.05). The ratio of sTfR to log (ferritin) was significantly higher (p<0.001) in the infants treated with rHuEpo than the controls. Intracellular organic and inorganic Pi changes were not affected by the Epo administration. The RBC 2,3-DPG seemed adequate in infants receiving rHuEpo. | en |
| heal.journalName | Eur J Haematol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
